Interpretación de las pruebas de laboratorio habituales en las enfermedades reumatológicas inflamatorias
EMC - Tratado de Medicina 01/2006; 10(1):1–9. DOI: 10.1016/S1636-5410(06)70375-0
Resulta difícil identificar la causa de las poliartritis en fase inicial, y no existe un acuerdo sobre las pruebas de laboratorio o radiológicas que se deben realizar en estos casos. Al revisar la literatura reciente, se ha podido comprobar que los artículos relativos a este tema, con cohortes de reumatismos en fase inicial, son menos de 30, y tratan sobre todo los factores reumatoideos, los anticuerpos anticitrulina y la tipificación del antígeno HLA. Una encuesta de opinión demuestra que, aunque existen grandes variaciones, las pruebas de laboratorio que se prescriben en las fases iniciales de los reumatismos inflamatorios son limitadas (NFS, VSG, CRP, fibrina, creatinina, ASAT, ALAT, proteinuria, hierro, CPK, serología de hepatitis B, de hepatitis C y de Lyme, TCA, anticuerpos antinucleares, factores reumatoideos, anticuerpos antiqueratina o anti-CCP y HLA B27). Una vez establecido el diagnóstico, el laboratorio sigue siendo esencial para la detección de afecciones viscerales y para el seguimiento de la inflamación.
- [Show abstract] [Hide abstract]
ABSTRACT: To investigate whether the determination of serum procalcitonin (PCT) in systemic autoimmune disease will help to discriminate invasive infection from highly active underlying disease. Three hundred ninety-seven serum samples, from 18 patients with systemic lupus erythematosus (SLE) and 35 patients with systemic antineutrophil cytoplasmic antibody-associated vasculitis (AAV), were analyzed. Clinical disease activity was assessed by the Systemic Lupus Activity Measure in SLE patients and by the Birmingham Vasculitis Activity Score in AAV patients. Procalcitonin concentrations were determined in parallel with concentrations of neopterin, interleukin-6 (IL-6), and C-reactive protein (CRP). Additionally, serum creatinine values were obtained. In 321 of the 324 samples from the 42 patients with autoimmune disease but without systemic infection, serum PCT levels were within the normal range (i.e., <0.5 ng/ml), whereas the values for neopterin, IL-6, and CRP were elevated in patients with active underlying disease. All 16 systemic infections occurred in 11 patients with AAV, and were associated with PCT levels that were markedly elevated, to a mean +/- SD of 1.93 +/- 1.19 ng/ml. No correlation between the degree of renal impairment and PCT concentrations was seen. PCT may serve as a useful marker for the detection of systemic bacterial infection in patients with systemic autoimmune disease.Arthritis & Rheumatology 07/1997; 40(7):1250-6. DOI:10.1002/1529-0131(199707)40:7<1250::AID-ART9>3.0.CO;2-A · 7.76 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: To determine the usefulness of serum ferritin and glycosylated ferritin (GF) levels in diagnosing adult onset Still's disease (AOSD). We performed a retrospective multicenter study of 205 patients who had ferritin and GF assays in one hospital laboratory. Records of all patients were reviewed, and a standardized questionnaire used to extract all data available at the time of the assay. The clinicians' final diagnosis was also recorded. Patients were classified as having "certain AOSD" (based on Yamaguchi's criteria) or a control disease. The concordance of ferritin and GF levels with final diagnosis was evaluated. In total 49 AOSD and 120 control patients were eligible. The mean ferritin value was significantly higher in the AOSD group (4,752 +/- 9,599 microg/l) than in the control group (1,571 +/- 3,807 microg/l), p = 0.029. GF was significantly lower in AOSD patients (15.9 +/- 11.9%) than in the control group (31.5 +/- 18.7%), p < 0.001. The combination of a GF level of < or = 20% with ferritin above the upper limit of normal yielded a sensitivity of 70.5% and specificity of 83.2%. The combination of a GF level < or = 20% with ferritin 5 times normal produced a sensitivity of 43.2% and specificity of 92.9%. This latter combination allowed an AOSD diagnosis to be ruled out for 6 of the 8 control patients who met Yamaguchi's positive criteria. Ferritin and GF levels are powerful diagnostic markers of AOSD. They may be helpful in clinical practice for excluding differential diagnoses.The Journal of Rheumatology 03/2001; 28(2):322-9. · 3.19 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Trials of rheumatoid arthritis (RA) treatments report the average response in multiple outcome measures for treated patients. It is more clinically relevant to test whether individual patients improve with treatment, and this identifies a single primary efficacy measure. Multiple definitions of improvement are currently in use in different trials. The goal of this study was to promulgate a single definition for use in RA trials. Using the American College of Rheumatology (ACR) core set of outcome measures for RA trials, we tested 40 different definitions of improvement, using a 3-step process. First, we performed a survey of rheumatologists, using actual patient cases from trials, to evaluate which definitions corresponded best to rheumatologists' impressions of improvement, eliminating most candidate definitions of improvement. Second, we tested 20 remaining definitions to determine which maximally discriminated effective treatment from placebo treatment and also minimized placebo response rates. With 8 candidate definitions of improvement remaining, we tested to see which were easiest to use and were best in accord with rheumatologists' impressions of improvement. The following definition of improvement was selected: 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute-phase reactant. Additional validation of this definition was carried out in a comparative trial, and the results suggest that the definition is statistically powerful and does not identify a large percentage of placebo-treated patients as being improved. We present a definition of improvement which we hope will be used widely in RA trials.Arthritis & Rheumatology 07/1995; 38(6):727-35. · 7.76 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.